Actuate Therapeutics Common Stock Performance
| ACTU Stock | 4.41 0.09 2.08% |
The firm shows a Beta (market volatility) of 1.91, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Actuate Therapeutics will likely underperform. At this point, Actuate Therapeutics has a negative expected return of -0.38%. Please make sure to confirm Actuate Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Actuate Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Actuate Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 2.08 | Five Day Return (6.77) | Year To Date Return (26.87) | Ten Year Return (48.78) | All Time Return (48.78) |
1 | Disposition of 50000 shares by Beitzel George B of Actuate Therapeutics, at 1.49 subject to Rule 16b-3 | 11/21/2025 |
2 | Backbone Potential Actuates Elraglusib Shows Promise vs. Pancreatic Cancer - GEN - Genetic Engineering and Biotechnology News | 11/25/2025 |
3 | Research Analysts Weekly Ratings Updates for Actuate Therapeutics | 12/03/2025 |
4 | Disposition of 10000 shares by Beitzel George B of Actuate Therapeutics, at 1.99 subject to Rule 16b-3 | 12/18/2025 |
5 | Disposition of 280000 shares by Thomson Todd S of Actuate Therapeutics at 5.8 subject to Rule 16b-3 | 01/05/2026 |
6 | Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with... | 01/12/2026 |
7 | Actuate Therapeutics, Inc.s market cap dropped US13m last week Private equity firms bore the brunt | 02/04/2026 |
| Begin Period Cash Flow | 3 M | |
| Free Cash Flow | -21.8 M |
Actuate Therapeutics Relative Risk vs. Return Landscape
If you would invest 590.00 in Actuate Therapeutics Common on November 10, 2025 and sell it today you would lose (149.00) from holding Actuate Therapeutics Common or give up 25.25% of portfolio value over 90 days. Actuate Therapeutics Common is currently does not generate positive expected returns and assumes 4.3301% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Actuate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Actuate Therapeutics Target Price Odds to finish over Current Price
The tendency of Actuate Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.41 | 90 days | 4.41 | about 98.0 |
Based on a normal probability distribution, the odds of Actuate Therapeutics to move above the current price in 90 days from now is about 98.0 (This Actuate Therapeutics Common probability density function shows the probability of Actuate Stock to fall within a particular range of prices over 90 days) .
Actuate Therapeutics Price Density |
| Price |
Predictive Modules for Actuate Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Actuate Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Actuate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Actuate Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Actuate Therapeutics is not an exception. The market had few large corrections towards the Actuate Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Actuate Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Actuate Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.7 | |
β | Beta against Dow Jones | 1.91 | |
σ | Overall volatility | 0.84 | |
Ir | Information ratio | -0.15 |
Actuate Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Actuate Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Actuate Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Actuate Therapeutics generated a negative expected return over the last 90 days | |
| Actuate Therapeutics has high historical volatility and very poor performance | |
| Actuate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (27.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Actuate Therapeutics generates negative cash flow from operations | |
| Actuate Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 16.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Actuate Therapeutics, Inc.s market cap dropped US13m last week Private equity firms bore the brunt |
Actuate Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Actuate Stock often depends not only on the future outlook of the current and potential Actuate Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Actuate Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 19.5 M | |
| Cash And Short Term Investments | 8.6 M | |
| Shares Float | 8.4 M |
Actuate Therapeutics Fundamentals Growth
Actuate Stock prices reflect investors' perceptions of the future prospects and financial health of Actuate Therapeutics, and Actuate Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Actuate Stock performance.
| Return On Asset | -3.49 | ||||
| Current Valuation | 109.05 M | ||||
| Shares Outstanding | 23.24 M | ||||
| Price To Book | 9.37 X | ||||
| EBITDA | (25.16 M) | ||||
| Net Income | (27.29 M) | ||||
| Total Debt | 404.99 K | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (21.84 M) | ||||
| Earnings Per Share | (3.11) X | ||||
| Market Capitalization | 136.67 M | ||||
| Total Asset | 9.32 M | ||||
| Retained Earnings | (132.38 M) | ||||
| Working Capital | 405.4 K | ||||
About Actuate Therapeutics Performance
Assessing Actuate Therapeutics' fundamental ratios provides investors with valuable insights into Actuate Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Actuate Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.37) | (3.54) | |
| Return On Capital Employed | (56.08) | (53.28) | |
| Return On Assets | (3.37) | (3.54) | |
| Return On Equity | (301.17) | (286.12) |
Things to note about Actuate Therapeutics performance evaluation
Checking the ongoing alerts about Actuate Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Actuate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Actuate Therapeutics generated a negative expected return over the last 90 days | |
| Actuate Therapeutics has high historical volatility and very poor performance | |
| Actuate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (27.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Actuate Therapeutics generates negative cash flow from operations | |
| Actuate Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 16.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Actuate Therapeutics, Inc.s market cap dropped US13m last week Private equity firms bore the brunt |
- Analyzing Actuate Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Actuate Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Actuate Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Actuate Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Actuate Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Actuate Therapeutics' stock. These opinions can provide insight into Actuate Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics' price analysis, check to measure Actuate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics is operating at the current time. Most of Actuate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics' price. Additionally, you may evaluate how the addition of Actuate Therapeutics to your portfolios can decrease your overall portfolio volatility.